Catherine Crenn-Hebert

Catherine Crenn-Hebert

Auto-generated profile, based on publicly available information

Catherine Crenn-Hebert

Louis-Mourier Hospital, Department of Gynecology and Obstetrics, Assistance Publique-Hôpitaux de Paris, Colombes;Regional Health Agency of Ile de France (ARS-IDF), Paris, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Journal of Gynecology Obstetrics and Human Reproduction
Verified
Journal Article
Closed access
PBP. Blanc-Petitjean
P. Blanc-Petitjean
MSM. Salomé
M. Salomé
CDC. Dupont
C. Dupont
CCC. Crenn-Hebert
C. Crenn-Hebert
AGA. Gaudineau
A. Gaudineau
CRC. Le Ray
C. Le Ray

23 March 2020 in Paediatric and Perinatal Epidemiology
Verified
Journal Article
Closed access
PDF file
ELElodie Lebreton
Elodie Lebreton
CCCatherine Crenn‐Hébert
Catherine Crenn‐Hébert
CMClaudie Menguy
Claudie Menguy
EHElizabeth A. Howell
Elizabeth A. Howell
JGJeffrey B. Gould
Jeffrey B. Gould
JZJennifer Zeitlin
Jennifer Zeitlin

1 December 2020 in Gynécologie Obstétrique Fertilité & Sénologie
Verified
Journal Article
Closed access
EAElie Azria
Elie Azria
PSPriscille Sauvegrain
Priscille Sauvegrain
JBJ. Blanc
J. Blanc
CCC. Crenn-Hebert
C. Crenn-Hebert
JFJ. Fresson
J. Fresson
CDC. Deneux-Tharaux
C. Deneux-Tharaux

19 November 2021 in Paediatric and Perinatal Epidemiology
Verified
Journal Article
Closed access
PDF file
ELElodie Lebreton
Elodie Lebreton
CMClaudie Menguy
Claudie Menguy
JFJeanne Fresson
Jeanne Fresson
NENatalia N. Egorova
Natalia N. Egorova
CHCatherine Crenn Hebert
Catherine Crenn Hebert
JZJennifer Zeitlin
Jennifer Zeitlin

1 October 2017 in Revue D'Épidémiologie Et de Santé Publique
Verified
Journal Article
Closed access
ASA. Serfaty
A. Serfaty
SBS. Baron
S. Baron
CCC. Crenn-Hebert
C. Crenn-Hebert
YBY. Barry
Y. Barry
STS. Tala
S. Tala

27 December 2024 in European Psychiatry
Verified
Journal Article
Open access
PDF file
ADAlexandra Doncarli
Alexandra Doncarli
VDVirginie Demiguel
Virginie Demiguel
CRCamille Le Ray
Camille Le Ray
CDCatherine Deneux-Tharaux
Catherine Deneux-Tharaux
ELElodie Lebreton
Elodie Lebreton
MGMembers of the ENP2021 Study Group
Members of the ENP2021 Study Group
Background: Postpartum anxiety (PPA) symptoms have harmful effects on child development and mother–infant interactions. Accordingly, in-depth knowledge of associated risk factors is crucial for prevention policies. This study aimed to estimate PPA symptom prevalence at 2 months and to identify associated risk factors in a representative sample of all women who gave birth in France in 2021, and in two subgroups: women with no postpartum depression (PPD) symptoms, and those with no history of mental health care. Methods: Among the 12,723 women included in the representative French national perinatal survey 2021ENP, 7,133 completed the Edinburgh Postnatal Depression Scale (EPDS) self-administered questionnaire – including three anxiety-specific items (EPDS-3A) – at 2 months postpartum. We estimated the adjusted prevalence ratios (aPR) of PPA symptoms using Poisson regression models with robust variance. Results: PPA symptom prevalence at 2 months was 27.6% (95% CI [26.5–28.8]). Associated risk factors were: age ≤ 34 years (maximum aPR = 1.38 [1.22–1.58] obtained for persons aged 25–29 years vs. 35–39 years), poorer health literacy (1.15 [1.07–1.23]), a history of medical termination of pregnancy (1.32 [1.05–1.68]), psychological (1.31 [1.17–1.47]) or psychiatric (1.42 [1.24–1.63]) care history since adolescence, nulliparity (1.23 [1.12–1.35]), no weight gain or loss (1.29 [1.03–1.61] vs. 9–15 kg gain) or gain ≥23 kg (1.20 [1.00–1.43]) during pregnancy, ≥3 pregnancy-related emergency consultations (1.16 [1.03–1.31] vs. none), poor/good support during pregnancy, (1.16 [1.00–1.34] and 1.15 [1.05–1.26], respectively, vs. very good), sadness (1.52 [1.36–1.69]), anhedonia (1.48 [1.27–1.72]), or both (1.99 [1.79–2.21]) during pregnancy, not at all/not very satisfied with pain management during childbirth (1.16 [1.01–1.32] vs. quite/very satisfied). Similar risk factors were found in the ‘no PPD symptoms’ and ‘no history of mental health care’ subgroups. Conclusions: Estimated PPA symptom prevalence at 2 months in our study sample was 27.6%. The risk factors we identified may guide future prevention policies.